These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 28646324

  • 1. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH, Singh SK, Nguyen TTTN, Roeffen W, Yang F, Lissau C, Madsen SM, Vrang A, Tiendrebeogo RW, Kana IH, Sauerwein RW, Theisen M, Rand KD.
    Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
    [Abstract] [Full Text] [Related]

  • 2. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies.
    Singh SK, Roeffen W, Andersen G, Bousema T, Christiansen M, Sauerwein R, Theisen M.
    Vaccine; 2015 Apr 15; 33(16):1981-6. PubMed ID: 25728318
    [Abstract] [Full Text] [Related]

  • 3. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.
    Roeffen W, Theisen M, van de Vegte-Bolmer M, van Gemert G, Arens T, Andersen G, Christiansen M, Sevargave L, Singh SK, Kaviraj S, Sauerwein R.
    Malar J; 2015 Nov 09; 14():443. PubMed ID: 26552428
    [Abstract] [Full Text] [Related]

  • 4. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
    Baptista BO, de Souza ABL, Riccio EKP, Bianco-Junior C, Totino PRR, Martins da Silva JH, Theisen M, Singh SK, Amoah LE, Ribeiro-Alves M, Souza RM, Lima-Junior JC, Daniel-Ribeiro CT, Pratt-Riccio LR.
    Malar J; 2022 Jan 04; 21(1):6. PubMed ID: 34983540
    [Abstract] [Full Text] [Related]

  • 5. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
    Agrawal A, Bisharyan Y, Papoyan A, Bednenko J, Cardarelli J, Yao M, Clark T, Berkmen M, Ke N, Colussi P.
    Protein Expr Purif; 2019 Jan 04; 153():7-17. PubMed ID: 30081196
    [Abstract] [Full Text] [Related]

  • 6. Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine.
    Singh SK, Roeffen W, Mistarz UH, Chourasia BK, Yang F, Rand KD, Sauerwein RW, Theisen M.
    Microb Cell Fact; 2017 May 31; 16(1):97. PubMed ID: 28569168
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M, Stoffel SA, Westerfeld N, Amacker M, Theisen M, Zurbriggen R, Pluschke G.
    Malar J; 2011 Dec 13; 10():359. PubMed ID: 22166048
    [Abstract] [Full Text] [Related]

  • 8. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
    Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, Madsen SM, Druilhe P.
    Vaccine; 2004 Mar 12; 22(9-10):1188-98. PubMed ID: 15003647
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
    Bélard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, de Salazar PM, Mürbeth RE, Milligan P, Imbault N, Imoukhuede EB, Theisen M, Jepsen S, Noor RA, Okech B, Kremsner PG, Mordmüller B.
    PLoS One; 2011 Mar 12; 6(7):e22525. PubMed ID: 21829466
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 11. The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria.
    Karch CP, Doll TAPF, Paulillo SM, Nebie I, Lanar DE, Corradin G, Burkhard P.
    J Nanobiotechnology; 2017 Sep 06; 15(1):62. PubMed ID: 28877692
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
    Amoah LE, Nuvor SV, Obboh EK, Acquah FK, Asare K, Singh SK, Boampong JN, Theisen M, Williamson KC.
    Parasit Vectors; 2017 Aug 23; 10(1):395. PubMed ID: 28835262
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.